Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.

Next Previous
Trial Profile

A Phase 4, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Oct 2013

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alvimopan (Primary)
  • Indications Intestinal disorders
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 22 Oct 2013 FDA approval for expanded use of alvimopan after surgery that includes bowel resection with primary anastomosis was primarily supported by data from this trial, according to a Cubist media release.
  • 17 Apr 2012 Results have been reported in a Cubist Pharmaceuticals media release.
  • 07 Dec 2011 Planned patients number (280) added as reported by M.D. Anderson Cancer Center.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top